Akari Therapeutics, Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.2	2.6	3.85	13.25	9.36
Cash & Short-Term Investments	5.2	2.6	3.85	13.25	9.36
Cash Growth	100.19%	-32.41%	-70.98%	41.55%	-33.40%
Accounts Receivable	-	-	-	2.95	4.98
Other Current Assets	0.26	0.35	0.5	-	-
Total Current Assets	5.46	2.95	4.34	16.2	14.34
Other Intangible Assets	34	39.18	0.01	0.02	0.02
Goodwill	8.43	8.43	-	-	-
Other Long-Term Assets	-	-	-	0.02	0.02
Total Assets	47.89	50.56	4.36	16.22	14.36
Accounts Payable	8.77	12.41	1.67	-	-
Accrued Expenses	2.34	3.14	1.57	-	-
Short-Term Debt	0.75	3.01	-	-	-
Current Portion of Long-Term Debt	-	0.25	-	-	-
Other Current Liabilities	0.49	1.11	1.35	7.85	-
Total Current Liabilities	12.35	19.91	4.58	7.85	6.09
Other Long-Term Liabilities	7.21	8.42	-	-	-
Total Long-Term Liabilities	7.21	8.42	-	-	-
Total Liabilities	19.56	28.33	4.58	10.98	6.09
Common Stock	-	5.32	1.32	0.74	0.48
Additional Paid-in Capital	234.32	212.71	174.75	-	125.06
Accumulated Other Comprehensive Income	58.56	51.46	51.15	52.19	52.19
Retained Earnings	-264.55	-247.25	-227.46	-191.34	-174.33
Shareholders' Equity	28.33	22.23	-0.23	5.24	8.27
Total Liabilities & Equity	47.89	50.56	4.36	16.22	14.36
Total Debt	0.75	3.26	0	0	0
Net Cash (Debt)	4.45	-0.66	3.85	13.25	9.36
Net Cash Growth	-	-	-70.98%	41.55%	-33.40%
Net Cash Per Share	0.13	-0.06	0.79	4.24	4.36
Book Value	28.33	22.23	-0.23	5.24	8.27
Book Value Per Share	0.84	1.86	-0.05	1.68	3.85
Tangible Book Value	-14.1	-25.38	-0.24	5.22	8.24
Tangible Book Value Per Share	-0.42	-2.13	-0.05	1.67	3.84

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q